American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 7, 2010, Pages

  Hammond, M Elizabeth H ^a   Hayes, Daniel F ^a   Dowsett, Mitch ^a   Allred, D Craig ^a   Hagerty, Karen L ^a   Badve, Sunil ^a   Fitzgibbons, Patrick L ^a   Francis, Glenn ^a   Goldstein, Neil S ^a   Hayes, Malcolm ^a   Hicks, David G ^a   Lester, Susan ^a   Love, Richard ^a   Mangu, Pamela B ^a   Mcshane, Lisa ^a   Miller, Keith ^a   Osborne, C Kent ^a   Paik, Soonmyung ^a   Perlmutter, Jane ^a   Rhodes, Anthony ^a   Sasano, Hironobu ^a   Schwartz, Jared N ^a   Sweep, Fred C G ^a   Taube, Sheila ^a   Torlakovic, Emina Emilia ^a   Valenstein, Paul ^a   Viale, Giuseppe ^a   Visscher, Daniel ^a   Wheeler, Thomas ^a   Williams, R Bruce ^a   Wittliff, James L ^a   Wolff, Antonio C ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ALGORITHM; ARTICLE; BREAST TUMOR; CANCER INVASION; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; PATHOLOGY; PRACTICE GUIDELINE; REPRODUCIBILITY; STANDARD; TREATMENT FAILURE; TUMOR RECURRENCE;

ALGORITHMS; BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 77954331064     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Fisher B, Redmond C, Brown A, et al: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1-6, 1981 (Pubitemid 11071188)
2. Fisher B, Redmond C, Brown A, et al: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1:227-241, 1983
3. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007 (Pubitemid 350232263)
4. Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966-978, 2000
5. Fleisher M, Dnistrian AM, Sturgeon CM, et al: Practice Guidelines and Recommendations for Use of Tumor Markers in the Clinic. Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Washington, DC, AACC Press, 2002
6. Wittliff JL: Steroid hormone receptors, in Pesce AJ Kaplan LA (eds): Methods in Clinical Chemistry. St Louis, MO, The CV Mosby Company, 1987, pp 767-795
7. Wittliff JL, Brown AM, Fisher B: Establishment of uniformity in steroid receptor determinations for protocol B-09 of the National Surgical Adjuvant Breast Project, in Sarfaty GA, Nash AR, Keightley DD (eds): Estrogen Receptor Assays in Breast Cancer: Laboratory Discrepancies and Quality Assurance. New York, NY, Masson Publishing USA, 1981, pp 27-42
8. Wittliff JL, Fisher G, Durant JR: Establishment of uniformity in steroid receptor analyses used in cooperative clinical trials of breast cancer treatment. Recent Results Cancer Res 71:198-206, 1980
9. McCormack VA, Dowsett M, Folkerd E, et al: Sex steroids, growth factors and mammographic density: A cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res 11: R38, 2009
10. Murray J, Young OE, Renshaw L, et al: A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women. Breast Cancer Res Treat 114:495-501, 2009
11. Bjornstrom L, Sjoberg M: Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19:833-842, 2005
12. Jensen EV, Desombre ER, Hurst DJ, et al: Estrogen-receptor interactions in target tissues. Arch Anat Microsc Morphol Exp 56:547-569, 1967
13. McGuire WL: Estrogen receptors in human breast cancer. J Clin Invest 52:73-77, 1973
14. McGuire W, Carbone PP, Sears ME, et al: Estrogen receptors in human breast cancer, in McGuire WL, Carbone PP, Vollmer EP (eds): Estrogen Receptors in Human Breast Cancer. New York, NY, Raven Press, 1975, pp 1-7
15. Pasic R, Djulbegovic B, Wittliff JL: Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding. J Clin Lab Anal 4:430-436, 1990
16. Dowsett M, Houghton J, Iden C, et al: Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17:818-826, 2006
17. McCarty KS Jr, Miller LS, Cox EB, et al: Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716-721, 1985
18. Barnes DM, Harris WH, Smith P, et al: Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74:1445-1451, 1996
19. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999
20. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study. Int J Cancer 89:111-117, 2000
21. Thomson CS, Twelves CJ, Mallon EA, et al: Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status. Breast 11:419-429, 2002
22. Regan MM, Viale G, Mastropasqua MG, et al: Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98:1571-1581, 2006
23. Massarweh S, Osborne CK, Creighton CJ, et al: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68:826-833, 2008
24. Clark GM, McGuire WL, Hubay CA, et al: Progesterone receptors as a prognostic factor in stage II breast cancer. N Engl J Med 309:1343-1347, 1983
25. Osborne CK, McGuire WL: Therapy for cancer of the breast: Current status of steroid hormone receptors. West J Med 130:401-407, 1979
26. Ravdin PM, Green S, Dorr TM, et al: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 10:1284-1291, 1992
27. Hayes DF: Markers of endocrine sensitivity. Breast Cancer Res 10: S18, 2008 (suppl 4)
28. Horwitz KB, McGuire WL: Predicting response to endocrine therapy in human breast cancer: A hypothesis. Science 189:726-727, 1975
29. Beatson GW: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 148:104-107, 1896
30. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
31. Ellis M, Hayes DF, Lippman ME: Treatment of metastatic breast cancer, in Harris J, Lippman M, Morrow M, et al (eds): Diseases of the Breast (ed 3). Philadelphia, PA, Lippincott Williams & Wilkins, 2004, pp 1101-1162
32. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006
33. Visvanathan K, Chlebowski RT, Hurley P, et al: American Society of Clinical Oncology Clinical Practice Guideline Update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235-3258, 2009
34. Haddow A, Watkinson JM, Paterson E: Influence of synthetic oestrogens upon advanced malignant disease. BMJ 2:393-398, 1944
35. Kennedy BJ: Massive estrogen administration in premenopausal women with metastatic breast cancer. Cancer 15:641-648, 1962
36. Ellis MJ, Gao F, Dehdashti F, et al: Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study. JAMA 302:774-780, 2009
37. Jordan C: Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther 24: A3-A16, 2002 (suppl A)
38. Mauri D, Pavlidis N, Polyzos NP, et al: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis. J Natl Cancer Inst 98:1285-1291, 2006
39. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 23:619-629, 2005
40. Lippman ME: An assessment of current achievements in the systemic management of breast cancer. Breast Cancer Res Treat 4:69-77, 1984
41. Anderson GF, Chu E: Expanding priorities: Confronting chronic disease in countries with low income. N Engl J Med 356:209-211, 2007
42. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon, France, IARC Press, 2004
43. Uy GB, Laudico AV, Fernandez AM, et al: Immuno-histochemical assay of hormone receptors in breast cancer at the Philippine General Hospital: Importance of early fixation of specimens. Philip J Surg Spec 62:123-127, 2007
44. Nichols HB, Trentham-Dietz A, Love RR, et al: Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev 14:41-47, 2005
45. Tan GH, Yip CH: In Love RR (ed), December 2008
46. Adebamowo CA, Famooto A, Ogundiran TO, et al: Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat 110:183-188, 2008
47. Mostafa MG: In Love RR (ed). Bangladesh, December 2008
48. Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059-1065, 2008
49. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
50. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43, 2007
51. Raam S, Gelman R, Cohen JL, et al: Estrogen receptor assay: Interlaboratory and intralaboratory variations in the measurement of receptors using dextran-coated charcoal technique: A study sponsored by ECOG. Eur J Cancer 17:643-649, 1981
52. Oxley DK, Haven GT, Wittliff JL, et al: Precision in estrogen and progesterone receptor assays: Results of the first CAP pilot survey. Am J Clin Pathol 78:587-596, 1982
53. Rhodes A, Jasani B, Balaton AJ, et al: Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: Correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 53:688-696, 2000
54. Rhodes A, Jasani B, Barnes DM, et al: Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 53:125-130, 2000
55. Francis GD, Dimech M, Giles L, et al: Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: Results of the RCPA Quality Assurance Program. J Clin Pathol 60:1277-1283, 2007
56. Cameron MA: Commission of Inquiry on Hormone Receptor Testing. St. John's, Newfoundland, Canada, Government of Newfoundland and Labrador, 2009
57. Seguin R: Breast cancer patients to be retested in Quebec. Globe and Mail, June 22, 2009
58. Canadian Cancer Society: Pathology tests related to breast cancer treatment. Canadian Cancer Society, Media Releases, June 3, 2009. http://www.cancer.ca/Quebec/About%20us/Media%20centre/QC-Media%20releases/ QC-Quebec%20media%20releases/Qc-pathology-tests-breast-cancer.aspx?sc-lang5en
59. Love RR, Duc NB, Allred DC, et al: Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 20:2559-2566, 2002
60. Badve SS, Baehner FL, Gray RP, et al: Estrogen-and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26:2473-2481, 2008
61. Viale G, Regan MM, Maiorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846-3852, 2007
62. Gelber RD, Gelber S: Facilitating consensus by examining patterns of treatment effects. International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG). Breast 18: S2-S8, 2009 (suppl 3)
63. Ibrahim M, Dodson A, Barnett S, et al: Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): Findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. Am J Clin Pathol 129:398-409, 2008
64. Fitzgibbons PL, Murphy DA, Hammond MEH, et al: Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med (in press)
65. McCarty KS Jr, Szabo E, Flowers JL, et al: Use of a monoclonal antiestrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46:4244s-4248s, 1986 (suppl)
66. DeSombre ER, Thorpe SM, Rose C, et al: Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res 46:4256s-4264s, 1986 (suppl)
67. Arpino G, Green SJ, Allred DC, et al: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study. Clin Cancer Res 10:5670-5676, 2004
68. Horiguchi J, Koibuchi Y, Iijima K, et al: Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer. Oncol Rep 14:1109-1116, 2005
69. Ellis MJ, Tao Y, Luo J, et al: Outcome prediction for estrogen receptorpositive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380-1388, 2008
70. Mohsin SK, Weiss H, Havighurst T, et al: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study. Mod Pathol 17:1545-1554, 2004
71. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
72. Viale G, Regan MM, Maiorano E, et al: Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 26:1404-1410, 2008
73. Cheang MC, Treaba DO, Speers CH, et al: Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637-5644, 2006
74. Phillips T, Murray G, Wakamiya K, et al: Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol 15:325-331, 2007
75. Osborne CK, Yochmowitz MG, Knight WA 3rd, et al: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884-2888, 1980
76. Knight WA 3rd, Osborne CK, McGuire WL: Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab 9:361-368, 1980
77. Cowen PN, Teasdale J, Jackson P, et al: Oestrogen receptor in breast cancer: Prognostic studies using a new immunohistochemical assay. Histopathology 17:319-325, 1990
78. Stendahl M, Ryden L, Nordenskjold B, et al: High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12:4614-4618, 2006
79. Lockwood CA, Ricciardelli C, Raymond WA, et al: A simple index using video image analysis to predict disease outcome in primary breast cancer. Int J Cancer 84:203-208, 1999
80. Esteban JM, Ahn C, Battifora H, et al: Quantitative immunohistochemical assay for hormonal receptors: Technical aspects and biological significance. J Cell Biochem Suppl 19:138-145, 1994
81. Yamashita H, Yando Y, Nishio M, et al: Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 13:74-83, 2006
82. Jalava P, Kuopio T, Huovinen R, et al: Immunohistochemical staining of estrogen and progesterone receptors: Aspects for evaluating positivity and defining the cutpoints. Anticancer Res 25:2535-2542, 2005
83. Ogawa Y, Moriya T, Kato Y, et al: Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: Analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer 11:267-275, 2004
84. Gown AM: Unmasking the mysteries of antigen or epitope retrieval and formalin fixation. Am J Clin Pathol 121:172-174, 2004
85. Nenci I, Beccati MD, Piffanelli A, et al: Detection and dynamic localisation of estradiol-receptor complexes in intact target cells by immunofluorescence technique. J Steroid Biochem 7:505-510, 1976
86. Diaz LK, Sneige N: Estrogen receptor analysis for breast cancer: Current issues and keys to increasing testing accuracy. Adv Anat Pathol 12:10-19, 2005
87. Yaziji H, Taylor CR, Goldstein NS, et al: Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol 16:513-520, 2008
88. Goldstein NS, Ferkowicz M, Odish E, et al: Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86-92, 2003
89. Scharl A, Vierbuchen M, Conradt B, et al: Immunohistochemical detection of progesterone receptor in formalin-fixed and paraffin-embedded breast cancer tissue using a monoclonal antibody. Arch Gynecol Obstet 247:63-71, 1990
90. Cavaliere A, Bellezza G, Ferri I, et al: Computer-assisted immunocytochemical determination of breast cancer steroid receptors: Frozen sections vs paraffin sections. Breast 11:476-483, 2001
91. Arber DA: Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers. Appl Immunohistochem Mol Morphol 10:183-186, 2002
92. Ibarra GR, Sananes C, Podeley G, et al: Estrogen receptor immunohistochemistry in formalin-fixed, paraffin-embedded breast tumor tissue: Enhanced sensitivity using a monoclonal antibody cocktail. Appl Immunohistochem Mol Morphol 3:202-208, 1995
93. Jensen V, Ladekari M: Immunohistochemical quantitation of oestrogen receptors and proliferative activity in oestrogen receptor positive breast cancer. J Clin Pathol 48:429-432, 1995
94. von Wasielewski, Mengel M, Nolte M, et al: Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis. Breast J 4:33-40, 1998
95. von Wasielewski R, Mengel M, Wiese B, et al: Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol 118:675-682, 2002
96. Taylor CR, Levenson RM: Quantification of immunohistochemistry: Issues concerning methods, utility and semiquantitative assessment II. Histopathology 49:411-424, 2006